APOE ε4 ARIA risk in lecanemab and donanemab therapy

APOE ε4 ARIA-E Risk Multipliers and the Case for Pre-Treatment Genetic Screening

APOE ε4 genotype status is the single most consequential patient-level variable in determining ARIA-E risk for individuals receiving anti-amyloid immunotherapy. The meta-analysis quantifies three distinct risk multipliers: APOE ε4 non-carriers face a 10.97x increased risk of ARIA-E compared to placebo, heterozygotes (one copy of the ε4 allele) face a 6.37x increased risk, and homozygotes (two copies) face a 10.84x increased risk. These figures overturn a common clinical assumption that homozygotes represent a simple linear escalation from heterozygotes — in fact, the non-carrier and homozygote risk profiles converge at the extreme end of the spectrum, while heterozygotes carry a comparatively lower, though still substantial, multiplier.

These risk multipliers carry direct prescribing implications. Clinicians cannot rely on a single ARIA risk tier for all patients; instead, genotype-stratified risk communication and monitoring intensity are required. For homozygous APOE ε4 carriers — who represent approximately 2–3% of the general population but a disproportionately high fraction of early-onset Alzheimer’s disease cases — the 10.84x multiplier places them in the highest-risk category, comparable to non-carriers despite the opposite end of the allele-dose spectrum. This non-linear relationship underscores the biological complexity of APOE ε4’s role in vascular amyloid dynamics and blood-brain barrier integrity.

Implications for Pre-Treatment Genetic Screening Protocols

Given these risk multipliers, pre-treatment APOE ε4 genotyping should be considered a standard component of the prescribing workup for both lecanemab and donanemab. A genotype-informed screening protocol serves three purposes: it enables accurate patient-level risk communication prior to informed consent; it determines the appropriate MRI monitoring intensity and frequency; and it informs the choice between treatment agents where clinical options exist. Patients identified as APOE ε4 homozygotes require the most intensive monitoring and the most explicit risk-benefit discussion, given their 10.84x ARIA-E multiplier. Heterozygotes, while carrying a lower 6.37x multiplier, still warrant heightened vigilance relative to the general population.

Clinicians should note that the non-linear risk pattern — where non-carriers and homozygotes share similarly elevated multipliers — may reflect distinct biological mechanisms. In non-carriers, the absence of the ε4 allele does not confer protection against ARIA-E; rather, it may reflect a different vascular amyloid burden profile. In homozygotes, the extreme allele dose drives elevated amyloid deposition and heightened vascular fragility, producing a convergent risk outcome through a different pathway. This distinction has practical implications: genetic counselling and risk communication should not imply that non-carrier status is protective, as the data show the opposite.

MRI Monitoring Schedule During Treatment Initiation: Rationale and Protocol

The recommended MRI monitoring schedule for patients initiating lecanemab or donanemab therapy consists of a baseline scan prior to the first dose, followed by monthly MRI scans for the first three months of treatment. This schedule is directly derived from the timing of ARIA onset observed in clinical trials, where the majority of ARIA-E events occur during early treatment cycles when amyloid plaque clearance is most active and vascular stress is highest.

The rationale for monthly scanning during the first three months is grounded in the kinetics of amyloid clearance. Both lecanemab and donanemab engage soluble and insoluble amyloid species, triggering an immune-mediated plaque removal process that generates transient vascular inflammation. This inflammatory response peaks during the early dosing phase, making the first three months the highest-risk window for ARIA development. Baseline MRI serves a dual purpose: it establishes a pre-treatment reference for any pre-existing white matter changes or microhaemorrhages that could confound ARIA interpretation, and it identifies patients with existing vascular pathology who may require modified dosing or closer surveillance.

After the initial three-month intensive monitoring period, the frequency of MRI surveillance can be adjusted based on the patient’s ARIA-E status and clinical trajectory. Patients who remain ARIA-free through month three may transition to less frequent monitoring, while those who develop asymptomatic ARIA-E require continued monthly surveillance and a clinical decision regarding dose modification or treatment interruption. The baseline scan’s role in identifying pre-existing microhaemorrhages is particularly important for APOE ε4 homozygotes, who have higher baseline cerebrovascular amyloid burden and may present with imaging findings that could be misattributed to treatment-related ARIA if no pre-treatment reference exists.

Lecanemab vs. Donanemab: Comparative Risk-Benefit Considerations for Patient Subgroup Selection

Lecanemab and donanemab differ fundamentally in their pharmacological approach to amyloid clearance, and these differences translate into distinct risk-benefit profiles that are relevant to patient subgroup selection. Lecanemab employs a gradual dose-escalation strategy, which produces a more controlled rate of amyloid plaque removal and is associated with a comparatively lower ARIA incidence profile. Donanemab uses a rapid plaque-clearance strategy that achieves faster amyloid reduction but may carry a higher ARIA burden, particularly in APOE ε4 carriers where vascular fragility is already elevated.

“The non-linear ARIA-E risk relationship — where APOE ε4 non-carriers (10.97×) and homozygotes (10.84×) share near-identical risk multipliers while heterozygotes (6.37×) occupy a distinct intermediate tier — demands that clinicians abandon simple allele-dose assumptions in favour of genotype-specific risk communication.”

Lecanemab’s Gradual Dose-Escalation Approach

Lecanemab’s dose-escalation protocol is designed to allow the brain’s vascular and immune systems to adapt to progressive amyloid clearance, reducing the acute inflammatory burden that underlies ARIA-E formation. This approach is particularly suited to patients with higher baseline ARIA risk — including APOE ε4 homozygotes and non-carriers who, despite lacking the ε4 allele, carry the 10.97x risk multiplier identified in the meta-analysis. The gradual approach also provides more decision points for clinical intervention: if early-cycle MRI reveals emerging ARIA-E, dose escalation can be paused or modified before reaching full therapeutic doses, limiting the severity of the imaging abnormality.

Donanemab’s Rapid Plaque-Clearance Strategy

Donanemab’s rapid clearance strategy is optimised for speed of amyloid reduction, which may translate into earlier cognitive benefit in patients with high amyloid burden. This approach may be most appropriate for APOE ε4 heterozygotes — who carry a 6.37x ARIA-E multiplier, the lowest of the three genotype groups — where the accelerated clearance benefit can be pursued with a somewhat more manageable ARIA risk profile. However, clinicians considering donanemab for heterozygotes should still implement the full baseline-plus-monthly MRI monitoring schedule during the first three months, as the absolute ARIA-E risk remains clinically meaningful at 6.37x above placebo.

For APOE ε4 homozygotes, the risk-benefit calculus is most complex. The 10.84x ARIA-E multiplier, combined with the highest baseline cerebrovascular amyloid burden, creates a scenario where both treatment agents carry substantial risk. In this subgroup, lecanemab’s gradual escalation approach provides the greatest margin for early ARIA detection and dose adjustment. The decision to treat APOE ε4 homozygotes with either agent should involve a multidisciplinary team including neurology, neuroradiology, and clinical genetics, with explicit documentation of the informed consent process given the elevated ARIA-E risk. According to FDA prescribing guidance for both agents, APOE ε4 homozygote status is identified as a risk factor requiring specific clinical consideration.

Unresolved Evidence Gaps: What the Meta-Analysis Could Not Answer

The meta-analysis identifies three major unresolved gaps that limit the generalisability and causal depth of the current ARIA risk stratification framework. These gaps are not minor caveats — they represent structural limitations in the existing evidence base that must be addressed before the clinical decision framework can be considered fully validated for real-world prescribing across all patient populations.

1. Limited Asian Cohort Representation

The clinical trials underpinning the ARIA risk multiplier data have been conducted predominantly in Western populations, with limited representation of Asian cohorts. This is a significant gap because APOE ε4 allele frequencies and associated cerebrovascular risk profiles differ across ethnic populations. The APOE ε4 allele frequency is lower in East Asian populations compared to European populations, according to data published by NIH, which means the risk multipliers derived from predominantly White trial populations may not accurately predict ARIA-E incidence in Asian patients. Furthermore, Asian patients may have different baseline cerebrovascular amyloid burden patterns and white matter characteristics that could modify ARIA expression and severity.

2. Short Follow-Up Periods

The follow-up periods in the trials included in the meta-analysis are insufficient to characterise long-term ARIA outcomes. Most trials assessed ARIA incidence over 18 months or fewer, leaving unanswered questions about whether ARIA-E risk diminishes after the initial treatment phase, whether late-onset ARIA events occur in patients who were ARIA-free during the monitored period, and whether cumulative amyloid clearance over multiple years modifies the vascular risk profile. Long-term follow-up data are essential for determining whether the monthly MRI monitoring schedule can safely be reduced after the first three months for all patients, or only for specific low-risk subgroups.

3. Absence of IPD Meta-Analyses to Validate Genotype-Efficacy Causality

The current meta-analysis relies on aggregate-level data from published trial results rather than individual patient data (IPD). This methodological limitation means that the observed association between APOE ε4 genotype and ARIA-E risk cannot be confirmed as causal at the individual patient level. IPD meta-analyses — which pool raw patient-level data from multiple trials — are needed to test whether APOE ε4 genotype independently predicts ARIA-E risk after controlling for confounders such as age, baseline amyloid burden, concomitant medications, and cardiovascular risk factors. Without IPD-level validation, the risk multipliers should be interpreted as population-level associations rather than individual-level predictions, as noted in methodological guidance from Cochrane.

Future Research Priorities for Precision Dosing and Long-Term Safety Monitoring

Optimising precision dosing and long-term safety monitoring for lecanemab and donanemab in real-world Alzheimer’s disease treatment settings requires a structured research agenda that directly addresses the gaps identified in the meta-analysis. Five priority areas emerge from the evidence base.

Priority 1: IPD Meta-Analyses for Genotype-Efficacy Causality

The most urgent research priority is the conduct of IPD meta-analyses pooling raw patient-level data from the major lecanemab and donanemab trials. These analyses should test whether APOE ε4 genotype independently predicts both ARIA-E risk and cognitive efficacy outcomes, after adjustment for key confounders. Establishing genotype-efficacy causality — not just association — is essential for justifying genotype-stratified dosing protocols and for determining whether the ARIA risk multipliers identified in the meta-analysis are stable across different patient populations and trial contexts. Collaborative data-sharing frameworks, such as those facilitated by EMA‘s clinical data transparency initiatives, could accelerate this work.

Priority 2: Precision Dosing Protocols Stratified by APOE ε4 Genotype

Current prescribing of lecanemab and donanemab uses uniform dosing protocols that do not formally account for APOE ε4 genotype status beyond general safety warnings. Future research should develop and validate genotype-stratified dosing protocols that adjust the rate of dose escalation, the target maintenance dose, and the inter-dose interval based on the patient’s ARIA-E risk multiplier. For APOE ε4 homozygotes — who carry a 10.84x ARIA-E risk — a more conservative escalation schedule with extended dose intervals may reduce ARIA incidence without sacrificing long-term efficacy, though this hypothesis requires prospective validation.

Priority 3: Expanded Trial Representation for Asian and Underrepresented Populations

Future trials and real-world registry studies must recruit representative samples of Asian and other underrepresented populations to determine whether the ARIA-E risk multipliers are generalisable across ethnic groups. This is not merely a matter of scientific completeness; it has direct implications for prescribing in countries such as Japan, South Korea, and China, where lecanemab has received or is seeking regulatory approval and where the APOE ε4 allele frequency and cerebrovascular disease burden profiles differ from those of Western trial populations. The WHO‘s guidance on inclusive clinical trial design provides a framework for addressing population representation gaps in future study protocols.

Priority 4: Long-Term Real-World Safety Monitoring Registries

The short follow-up periods in existing trials necessitate the establishment of long-term real-world safety monitoring registries for patients receiving lecanemab and donanemab outside of clinical trial settings. These registries should capture ARIA incidence and severity across the full treatment duration, MRI findings beyond the initial three-month monitoring window, cognitive outcomes stratified by APOE ε4 genotype, and any late-onset adverse events not captured in the trial follow-up period. Registry data will be essential for validating whether the three-month intensive MRI monitoring protocol is sufficient, or whether extended surveillance is required for high-risk subgroups.

Priority 5: Biomarker Development for ARIA Prediction

Beyond APOE ε4 genotyping, future research should identify additional biomarkers that can refine individual-level ARIA risk prediction. Candidate biomarkers include plasma amyloid-β and tau levels, cerebral microhaemorrhage burden on baseline MRI, and markers of blood-brain barrier integrity. A multi-biomarker risk score that integrates APOE ε4 genotype with these additional variables could provide greater predictive precision than genotype alone, enabling more nuanced prescribing decisions — particularly for patients in the intermediate-risk heterozygote category where the treatment choice between lecanemab and donanemab is most contested.